Sophia Genetics SA（SOPH）財務資料SOPHSophia Genetics SA

Evaluating the bottom line, SOPHiA GENETICS SA maintains a gross margin of 64.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.27%, while the net margin is -95.91%. These profitability ratios, combined with a Return on Equity (ROE) of -101.22%, provide a clear picture of how effectively SOPH converts its operational activities into shareholder value.

In the context of the broader market, SOPH competes directly with industry leaders such as SABR and RZLV. With a market capitalization of $625.69M, it holds a significant position in the sector. When comparing efficiency, SOPH's gross margin of 64.61% stands against SABR's 56.39% and RZLV's N/A. Such benchmarking helps identify whether SOPHiA GENETICS SA is trading at a premium or discount relative to its financial performance.

SOPHiA Genetics has shown a gross margin of 66.25% in Q2 2026 and a total revenue growth trajectory, with Q2 2026 revenue reaching $23.3 million, up 27% year-over-year. Despite ongoing losses, the company is expanding its market presence and partnerships.